A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45years of age.

Theresa E Hegmann,Emmanuel B Walter,Michael J Smith,James Campbell,Hana M El Sahly,Jennifer A Whitaker,C Buddy Creech,Irina V Ustyugova,Ana P Goncalvez,Aseem Pandey,Timothy Alefantis,Saranya Sridhar,Yoshikazu Honda-Okubo,Nikolai Petrovsky,Sharon E Frey,Getahun Abate,Grant Paulsen,Evan J Anderson,Christina A Rostad,Nadine Rouphael,Mamodikoe Makhene,Paul C Roberts,Bonifride Tuyishimire,Christopher Bryant,Patricia Winokur

doi:10.1016/j.vaccine.2025.126991

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45years of age.

Theresa E Hegmann, Emmanuel B Walter + Show 23 more

https://doi.org/10.1016/j.vaccine.2025.126991

Copy DOI

Export

Save

Share

Cite

Listen
Translate
Chat Pdf
Cite
Export
Share

Journal: Vaccine

Publication Date: Apr 1, 2025

#Quadrivalent Influenza Vaccine #Seasonal Influenza Vaccine #Breadth Of Immune Responses #Influenza Vaccine #Seasonal Influenza #Immune Responses #Neuraminidase Inhibition #Heterologous Strains #Adjuvanted Vaccines #Doses Of Influenza Vaccine

Abstract
Full-Text
Similar Papers

Abstract

Listen

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45years of age.

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Vaccine

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

Chat PDF

Full screen

Editage

Paperpal

R Discovery

Mind the Graph

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45years of age.

Abstract

Published Version

Similar Papers

More From: Vaccine